Improving the use of research evidence in guideline development: 11. Incorporating considerations of cost-effectiveness, affordability and resource implications by Edejer, Tessa Tan-Torres
BioMed  Central
Page 1 of 6
(page number not for citation purposes)
Health Research Policy and Systems
Open Access
Review
Improving the use of research evidence in guideline 
development: 11. Incorporating considerations of cost-
effectiveness, affordability and resource implications
Tessa Tan-Torres Edejer*
Address: Health Systems Financing, World Health Organization, CH-1211 Geneva 27, Switzerland
Email: Tessa Tan-Torres Edejer* - tantorrest@who.int
* Corresponding author    
Abstract
Background: The World Health Organization (WHO), like many other organisations around the world, has
recognised the need to use more rigorous processes to ensure that health care recommendations are
informed by the best available research evidence. This is the 11th of a series of 16 reviews that have been
prepared as background for advice from the WHO Advisory Committee on Health Research to WHO on how
to achieve this.
Objectives: We reviewed the literature on incorporating considerations of cost-effectiveness, affordability
and resource implications in guidelines and recommendations.
Methods:  We searched PubMed and three databases of methodological studies for existing systematic
reviews and relevant methodological research. We did not conduct systematic reviews ourselves. Our
conclusions are based on the available evidence, consideration of what WHO and other organisations are
doing and logical arguments.
Key questions and answers: When is it important to incorporate cost-effectiveness, resource
implications and affordability considerations in WHO guidelines (which topics)?
• For cost-effectiveness:
The need for cost/effectiveness information should be dictated by the specific question, of which several may
be addressed in a single guideline. It is proposed that the indications for undertaking a cost-effectiveness
analysis (CEA) could be a starting point for determining which recommendation(s) in the guideline would
benefit from such analysis.
• For resource implications/affordability:
The resource implications of each individual recommendation need to be considered when implementation
issues are being discussed.
How can cost-effectiveness, resource implications and affordability be explicitly taken into
account in WHO guidelines?
• For cost-effectiveness:
 If data are available, the ideal time to consider cost-effectiveness is during the evidence gathering and
synthesizing stage. However, because of the inconsistent availability of CEAs and the procedural difficulty
associated with adjusting results from different CEAs to make them comparable, it is also possible for cost-
effectiveness to be considered during the stage of developing recommendations.
 Depending on the quantity and quality and relevance of the data available, such data can be considered in a
qualitative way or in a quantitative way, ranging from a listing of the costs to a modelling exercise. At the very
least, a qualitative approach like a commentary outlining the economic issues that need to be considered is
necessary. If a quantitative approach is to be used, the full model should be transparent and comprehensive.
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• For resource implications/affordability:
 Resource implications, including health system changes, for each recommendation in a WHO guideline should
be explored. At the minimum, a qualitative description that can serve as a gross indicator of the amount of
resources needed, relative to current practice, should be provided.
How does one provide guidance in contextualizing guideline recommendations at the country
level based on considerations of cost-effectiveness, resource implications and affordability?
• All models should be made available and ideally are designed to allow for analysts to make changes in key
parameters and reapply results in their own country.
• In the global guidelines, scenarios and extensive sensitivity/uncertainty analysis can be applied.
Resource implications for WHO
• From the above, it is clear that guidelines development groups will need a health economist. There is need 
to ensure that this is included in the budget for guidelines and that there is in-house support for this as well.
Background
The World Health Organization (WHO), like many other
organisations around the world, has recognised the need
to use more rigorous processes to ensure that health care
recommendations are informed by the best available
research evidence. This is the 11th of a series of 16 reviews
that have been prepared as background for advice from
the WHO Advisory Committee on Health Research to
WHO on how to achieve this. In this paper we address the
following questions:
• When is it important to incorporate cost-effectiveness,
resource implications and affordability considerations in
WHO guidelines (which topics)?
￿ How can cost-effectiveness, resource implications and
affordability be explicitly taken into account in WHO
guidelines?
￿ How does one provide guidance in contextualizing
guideline recommendations at the country level based on
considerations of cost-effectiveness, resource implications
and affordability?
￿ What are the resource implications of the answers to
these questions for WHO?
What is WHO doing now?
In 2003, the Guidelines for WHO Guidelines [1] recom-
mended that both cost-effectiveness and resource implica-
tions of guideline recommendations be considered when
developing WHO guidelines. With the primary audience
being Ministry of Health officials with a mandate to
improve population health rather than the health of indi-
viduals, such concerns were considered to be appropriate.
The guidelines (see Additional file 1 for relevant portions)
states very briefly that cost-effectiveness is to be consid-
ered during the stage of formulation of the recommenda-
tions and that the recommendations could be expressed
in terms of scenarios (for countries with limited versus
some resources). It also recommends that 1–2 experts in
cost-effectiveness analysis (CEA) be involved in the tech-
nical guidelines development group. Finally, in the third
stage or the localization phase in-country, it suggests that
WHO provide technical assistance for countries to use
their own or regional cost-effectiveness information and
that WHO also provide information on financial costs of
implementing the recommendations.
There has been some mention of cost-effectiveness in a
few guidelines that were issued since 2003 and that claim
to have used the Guidelines for WHO Guidelines. The
2003 WHO/ISH guidelines [2] had general sections on
cost-effectiveness and resource implications of the recom-
mendations. More recently, the WHO "guidelines" on
hand hygiene in health care [3] also included information
on economic burden of poor hygiene, cost-effectiveness
and resource implications of recommendations. Another
example, the malaria treatment guidelines [4] specifically
state that cost-effectiveness studies were not included for
consideration because there were very few completed
studies relating to the interventions being considered, and
that the prices of the anti-malarial drugs were fluid, "ren-
dering such studies unreliable."
What other organizations are doing?
It is clear that cost-effectiveness and/or cost implications
of recommendations are recognized in guideline develop-
ment. The US Preventive Services Task Force [5] lists sev-
eral reasons why CEA is useful in guideline development:
1. Quantifying the differences between two or more effec-
tive services for the same conditionHealth Research Policy and Systems 2006, 4:23 http://www.health-policy-systems.com/content/4/1/23
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2. Illustrating the impact of delivering a given interven-
tion at different intervals, different ages, or to different risk
groups
3. Evaluating the potential role of new technologies
4. Identifying key conditions that must be met to achieve
the intended benefit of an intervention
5. Incorporating preferences for intervention outcomes
6. Developing a ranking of services in order of their costs
and expected benefits
The AGREE guidelines appraisal instrument [6], on which
the WHO checklist was loosely based, includes the cost
impact of guideline recommendations under their appli-
cability criteria.
To actually gauge what other organizations are doing with
respect to cost-effectiveness/costs in guideline develop-
ment, one can review the guidelines that have been issued
by these organizations and/or review their documented
methods for guideline development. It is hoped that there
is consistency between the two. In 1999, 279 guidelines
that were published in peer-reviewed literature were
reviewed [7]. Only 41.6% made any mention of projected
effects on health care costs, and only 14.3% quantified
these estimates in any way. A 2002 study on the incorpo-
ration of published cost-effectiveness analysis in pub-
lished clinical guidelines showed that, using guidelines as
the unit of analysis, 9 of 35 (26%) incorporated at least 1
economic analysis of above-average quality in the text and
11 of 35 (31%) incorporated at least 1 in the references
[8]. Finally, a search of the database of the National
Guideline Clearinghouse [9] showed that of 1616 guide-
lines published between 2000–2005, only 369 or 23%
had a formal cost analysis.
For a review of methods, a 2003 survey [10] of 18 clinical
practice guideline development agencies showed that six
included costs/cost containment/cost-effectiveness in
their objectives but only three routinely included health
economists in their guideline development groups
(NHRMC in Australia, SBU in Sweden, and North of Eng-
land). The AGREE prototype electronic library shows
some illustrative excerpts specifically mentioning costs
from the methodologies of five national agencies. More
detailed information on the use of costs/cost-effectiveness
information by guidelines agencies is available (see Addi-
tional file 2).
To what extent these organizations routinely and explic-
itly use costs/CEA in their guidelines is not clear. More
information is needed on the actual experience of these
organizations in incorporating costs/cost-effectiveness
information during their guideline development process
(e.g. lessons learned) [11] and an assessment of whether
economic evaluations have provided added value to their
guidelines [12].
Methods
The methods used to prepare this review are described in
the introduction to this series [13]. Briefly, the key ques-
tions addressed in this paper were vetted amongst the
authors of the series of articles and the ACHR Subcommit-
tee on the Use of Research Evidence (SURE). We did not
conduct full systematic reviews. We searched PubMed and
three databases of methodological studies (the Cochrane
Methodology Register, the US National Guideline Clear-
inghouse, and the Guidelines International Network for
existing systematic reviews and relevant methodological
research that address these questions. The answers to the
questions are our conclusions based on the available evi-
dence, consideration of what WHO and other organisa-
tions are doing, and logical arguments.
For this review PubMed was searched using the following
text word searches: costs and generalizability, practice
guidelines and cost-effectiveness analysis and combina-
tions thereof. Using the same search words, the Internet
search machine, Google, was also used to search for
unpublished documents. Websites of known repositories
of guidelines, of organizations of guideline agencies, and
of pioneer/well-known guideline development agencies
were visited. References in key documents that had titles
which could be probably relevant were also pursued. A
few times, when it was evident that an author had this as
his/her special area of interest, a search using his/her
name in connection with guidelines was also done. Papers
were included if they described guidelines that included
cost-effectiveness information, or described methods of
guideline agencies to incorporate costs/resource implica-
tions/CEA information.
The information collected during the review was then syn-
thesized where relevant for each question and was used as
the basis to draw the implications for WHO guidelines.
Findings
When is it important to incorporate considerations of cost-
effectiveness and resource implications of 
recommendations in WHO guidelines (which topics)?
The need for cost-effectiveness information should be dic-
tated by the specific question of which several may be
addressed in one guideline alone. It is proposed that the
indications for undertaking a cost-effectiveness analysis
could be a starting point for determining which recom-
mendation(s) in the guideline would benefit from such
analysis [14]. From the review, NHRMC states explicitlyHealth Research Policy and Systems 2006, 4:23 http://www.health-policy-systems.com/content/4/1/23
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that "the challenge is to focus on the decision points that
are of key importance in an economic sense and pinpoint
the nature of economic information needed to address
these questions. The key decisions concern health care
that contributes significantly to the total cost of an option,
options with very different costs or care that contributes
significantly to health outcomes. On the other hand, deci-
sions are unimportant if they concern health care that is
uncontroversial, options that are not economically viable
or options for which there are no large resource implica-
tions." [15]
The UK National Institute for Health and Clinical Excel-
lence (NICE) extends this concept by adopting a value of
analysis approach where aside from "the overall 'impor-
tance' of the recommendation (which is a function of the
number of patients affected and the potential impact on
costs and health outcomes per patient)", they also suggest
evaluating "the current extent of uncertainty over cost-
effectiveness and the likelihood that analysis will reduce
this uncertainty" [16].
Implications for WHO guidelines
At the scoping stage, the assistance of an experienced
health economist who is familiar with the area of interest
would be needed and a selective identification of the
issues needing CEA could be done. If CEA is not initially
identified during the scoping stage as a clear need, this
issue needs to be revisited again at the evidence, recom-
mendations and peer review stage.
On the other hand, the resource implications of each indi-
vidual recommendation needs to be considered when
implementation issues are being discussed. This may be
done at the global guideline level, through the use of sce-
narios, and at the local adaptation or country level.
How can cost-effectiveness and affordability be explicitly 
taken into account in WHO guidelines?
There are different points in the guideline development
process that cost-effectiveness and resource implications
of guidelines recommendations can be considered. The
first phase is the evidence phase and to the extent possi-
ble, this is where cost-effectiveness information should be
considered.
As in questions on effectiveness, the question can be
raised as to why conduct a review of CEAs rather than
identify a single study that addresses the question? "CEAs
vary widely in their methods and assumptions. Because of
this variation, systematically reviewing CEAs provides sev-
eral benefits. First, because CEAs draw on a variety of cost
and effectiveness data sources to develop input parame-
ters, a systematic review can identify which analyses use
the best available evidence for key inputs and are therefore
the most evidence based. Second, because the credibility
of CEAs rests on their quality, a critical review of CEAs and
a rating of the quality of each allow for identifying the
most methodologically rigorous studies. Third, a compre-
hensive review can identify the studies that best address
the question being asked. Fourth, comparatively assessing
CEAs can help to identify variables and methods that sig-
nificantly influence the estimated benefits and cost effec-
tiveness of an intervention. For instance, some CEAs
might assume no harms from a given intervention, while
others might assume that the intervention has significant
harms. Comparing these studies side by side may provide
insight into how the assumption or lack of assumption of
harm affects the estimated benefit of the intervention.
While some assumptions are varied within a single study
using sensitivity analysis, most CEAs provide a limited
number of sensitivity analyses. Thus, systematically
reviewing CEAs may help identify, through a side-by-side
comparison that amounts to a "virtual sensitivity analy-
sis," the impact of different assumptions on the benefits
of a given intervention. Finally, the more high-quality,
independently conducted CEAs there are for a given inter-
vention, the more convincing the evidence." [17]
In doing a systematic review of economic evaluations, the
first step is to search for the literature. There are available
resources on the internet which list databases and compi-
lations of economic evaluations [18]. In addition, there
has been a systematic evaluation in terms of sensitivity
and specificity of different search strategies for economic
evaluations [19].
In extracting data, considerable progress has been
reported with development of a systematic process of
adjustments of results from different studies to make
them comparable. The Task Force on Community Preven-
tive Services admits that "no process of adjustment or
other means of reviewing existing economic evaluations is
flawless." But it makes the point that to adjust data to
make it comparable is better than to "(1) ignore economic
information entirely; (2) attempt to use non-comparable
data; or (3) adjust in ways that are not systematic or
explicit" [20].
Some work has also been done in terms of very simple vis-
ual methods to present summaries of cost-effectiveness
analysis [21]. Despite all of these advances methodologi-
cally, the current situation shows however, that there is
limited availability and variable quality of relevant CEAs
[22].
Implications for WHO guidelines
If data is available, the ideal time to consider CEA is dur-
ing the evidence gathering and synthesizing stage. How-
ever, because of the inconsistent availability of CEAs andHealth Research Policy and Systems 2006, 4:23 http://www.health-policy-systems.com/content/4/1/23
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the procedural difficulty associated with adjusting results
from different CEAs to make them comparable [20] it is
also possible for CEA to be considered during the stage of
developing recommendations. This is also consistent with
the GRADE approach [23]. At this stage, the information
of the resource implications and outcomes of the recom-
mended interventions can be considered simultaneously.
Depending on the quantity and quality and relevance of
the data available, such data can be considered in a qual-
itative way or in a quantitative way, ranging from a listing
of the costs to a modelling exercise [24,25]. At the very
least, a qualitative approach like a commentary outlining
the economic issues that need to be considered is neces-
sary [26]. If a quantitative approach is to be used, the full
model should be transparent, be made available and
extensive uncertainty/sensitivity analysis built-in so as to
allow analysts to selectively reapply results in their own
country, as in the WHO-CHOICE contextualization tool
[27].
How does one provide guidance in contextualizing 
guideline recommendations at the country level based on 
considerations of cost-effectiveness and affordability?
For cost-effectiveness, there are concerns about the gener-
alizability of results from a single CEA or even a systematic
review of a CEA. A review of sources of variability fre-
quently mentions volume and costs of resources con-
sumed as a source of variability [28]. Not as much work
has been done on variability of outcomes. Very recently, a
checklist was developed for assessing variability or gener-
alizability to be able to translate information from one
developed country to another [29]. There is a need to pilot
test this, a revision or another instrument in developing
countries. For costs, more specifically prices, general prin-
ciples for adaptation are available [30].
Affordability or resource implications can be considered
in the global guidelines if it gives guidance by provision of
basic information that will allow guideline users to work
out the cost implications for their own service [25,15]. A
scenario approach can be used. Also, in this context,
WHO-CHOICE data and methods are useful for contextu-
alization [31]. Note that this exercise will also need to
include the health system implications of the recommen-
dations, from training, changes in supervision, monitor-
ing and evaluation, advocacy, etc. as seen in some recent
examples [32,33].
Implications for WHO
Resource implications, including health system changes,
for each recommendation in WHO guidelines should be
explored. At the minimum, a qualitative description that
can serve as a gross indicator of the amount of resources
needed, relative to current practice, should be provided.
Overall assessment of need for health economics expertise
In summary, the role of the health economist in a guide-
line development group is to:
￿ help to identify the clinical issues or questions for eco-
nomic analysis
￿ review economic literature
￿ carry out or commission cost-effectiveness analyses
￿ estimate the cost and resource implications of the rec-
ommendations.
"The relative weight given to each role will vary from
guideline to guideline. There may be large differences
between guidelines in respect of the literature available to
review: the size of the relevant economics literature, its rel-
evance, its quality, its timeliness, its generalisability. In
some areas there may be good-quality data that can be
used in economic models, whereas other areas may have
a dearth of such data." [16] Additionally, all throughout
the process, the health economist can educate the other
guideline development group about CEA and vice-versa,
through interaction with the guideline development
group members, s/he will be better able to work with an
improved understanding of the health issues being con-
sidered.
Implications for WHO
From the above, it is clear that guidelines development
groups will need access to a health economist. There is
need to ensure that this is budgeted for in the resources
and that there is in-house support for this as well.
Further work
There is a need to: 1) get more information on the actual
experience of guideline agencies in incorporating CEA in
guidelines; 2) assess the added value of economic evalua-
tions in guidelines by comparing recommendations with
and without CEA; 3) further expand the section on CEA
and resource implications in guidelines, including specifi-
cation of the minimum information that should be pro-
vided, in collaboration with health economists and
experienced guideline developers.
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